Year in review: 2014 was the year of the medtech IPO

December 10, 2014 By MassDevice staff

Click to enlarge

It was, as predicted, the year of the IPO for medical device companies, with 25 filing initial public offerings during 2014, according to a MassDevice.com analysis.

That’s a dramatic change from 2013, when just 4 companies filed for IPOs, according to VentureSource.

The frothy market isn’t just a win for investors in those newly public companies, because the favorable market conditions can increase valuations on M&A deals and provide another exit pathway for venture capitalists, which could in turn promote much-needed investment in the medtech space.

In 2013, the medical device industry saw just $2.5 billion invested in the space, making it the quietest year medical device investments since 2005.

“For medtech, exits have been phenomenal this year," Matthew Dolan, director of business development for Volcano (NSDQ:VOLC), said recently at our DeviceTalks West event. "We haven’t seen a year like this since, I don’t know, 2007, 2008, somewhere in there."

"If you’re a banker, you’re going around jazzed about how everything has been up probably on average about 30% or 40%, a couple pricing above range for the 1st time in a while and really doing well. I think that window is officially open," added Dolan, who was a banker with the Newport beach, Calif. investment firm Roth Capital Partners before joining Volcano.

Investors ought to be jazzed, too, with the return on their investments. The top 5 IPOs of the year returned a collective 36.3% on their offering prices, led by the largest of the year (see list below).

Nevro Corp. (NYSE:NVRO), which closed its initial public offering in early November with $144.9 million raised from issuing 8.05 million shares at $18 apiece, boasting the year’s top-grossing medical device IPO and its biggest return (90% as of market’s close yesterday). The Menlo Park, Calif.-based company was founded in 2006 and has been led since 2011 by ex-Medtronic (NYSE:MDT) COO Michael DeMane. The company has raised more than $153 million so far from backers including Johnson & Johnson (NYSE:JNJ), Covidien (NYSE:COV), Novo Nordisk and New Enterprise Assoc. A Series C round brought in $48 million last year.

Here’s a look at the Top 5 IPOs this year by gross amount (including any over-allotments), with their share price as of Dec. 9, 2014 and their return on the IPO price:

Nevro Corp. (NYSE:NVRO): $144.9 million, $34.20 (+90.0%)

K2M Group (NSDQ:KTWO): $132.4 million, $19.52 (+30.1%)

TriVascular Technologies (NSDQ:TRIV): $89.7 million, $13.48 (+12.3%)

Sientra (NSDQ:SIEN): $86.3 million, $16.51 (+10.1%)

Ocular Therapeutix (NSDQ:OCUL): $74.8 million, $18.04 (+38.8%)

The boost in IPOs in 2014 was not unexpected; in late 2013 Renaissance Capital predicted a robust year for public offerings.

"We anticipate another dynamic year for the US IPO market in 2014," Renaissance wrote in its annual wrap-up report. "With positive investor sentiment, low volatility levels and improving economic conditions setting the stage for another strong year for U.S. stocks, we expect the US IPO market to remain healthy in 2014."

CVRx CEO details the path from being engineer to medtech executive
Nadim Yared, CEO of CVRx[/caption] This week, CVRX reported positive six-month trial results for its Barostim Neo, an FDA-approved treatment for heart failure. The results follow years of close work between the agency and CVRx, one of the more ambitious startups in medtech. CVRx is targeting a huge clinical need with novel neuromodulation technology. In… […]
What’s next for nitinol tubing?
Nitinol’s unique properties have made it the darling of the medical device industry. A novel technique for mechanically joining nitinol to other metal tubing could reduce cost and mitigate risk. Mark Broadley, Viant Nitinol has revolutionized the medical device industry. With its flexible superelasticity, shape memory and biocompatibility, nitinol has become a go-to material for… […]
Report: Haemonetics’ blood-collection devices could leave particles in donors
A consortium of news outlets is questioning the safety of Haemonetics (NYSE:HAE) blood-collection devices, claiming that particles have been detected in donors whose plasma was extracted by the machines. According to a report in the Miami Herald, whistleblower documents indicate that more than 150 Haemonetics customer reports have been made regarding the presence of particles by plasma collection centers and heathcare… […]
Spinal Elements’ cervical fixation system wins FDA nod
Spine surgery technology developer Spinal Elements announced today that it received FDA clearance for its Sapphire X product for anterior cervical fixation. Sapphire X is comprised of integrated instrumentation and high-angulation screws designed to help surgeons perform a procedure while preserving the patient’s skeletal and muscle tissue. The instrumentation is designed to reduce procedural steps… […]
How COVID-19 impacts FDA interactions with medical device manufacturers
By Stewart Eisenhart, Emergo Group The US Food and Drug Administration may revise performance goals and timelines set under the Medical Device User Fee Amendments IV (MDUFA IV) as emergency efforts targeting the coronavirus pandemic take up more of the agency’s time. Get the full story here at the Emergo Group’s blog. The opinions expressed… […]
Switchback Medical adds ‘sandbox approach’ to device testing
Contract manufacturer Switchback Medical (Maple Grove, Minn.) today announced that it has added a new division. Switchback BioSim Innovations offers functional dynamic biosimulator model development, cell culture services and physician training, according to the company. Biosimulator models use animal and human tissue to create functional models, such as a pumping heart with working valves to… […]
Smith College team wins ventilator design challenge
A team of Smith College engineering alumnae, staff and faculty has won the CoVent-19 Challenge to design a rapidly deployable ventilator to address shortages caused by the COVID-19 pandemic, particularly in developing countries. A dozen anesthesiology resident physicians from Massachusetts General Hospital kicked off the public challenge April 1, attracting 200 entries. The 30-person team… […]
FDA gives certain device makers more time to add UDIs
The FDA said today that it will grant manufacturers of Class 1 and unclassified medical devices and certain others more time to add unique device identifiers (UDIs) to their products. These companies will now have until Sept. 24, 2022 to comply with the agency’s UDI rule, including standard date formatting, labeling and Global Unique Device… […]
Eurofins launches 10-minute COVID-19 exposure testing device
Eurofins (Paris:ERF.PA) announced today that it launched its rapid point-of-care testing devices to identify past exposure to COVID-19. The serology-based, finger-prick tests detect antibodies with a sensitivity of 94.5% from 19 days following the onset of symptoms, with results coming in just 10 minutes, according to a news release. Get the full story at our sister site,… […]
How is RF technology shaping the future of medtech?
RF technology, including microwaves, isn’t just about wireless communications or military radar these days. Times Microwave Systems experts point out that it is increasingly important when it comes to medtech. Many medical electronics systems such as magnetic resonance imaging (MRI) systems for cancer detection rely on RF/microwave technology. Times Microwave Systems (Wallingford, Conn.) is hosting… […]
Medical device litigation and COVID-19: What you need to know
The COVID-19 pandemic is creating a new set of medical device litigation challenges — but also a chance for an industry reset. One of Greenberg Traurig’s top medtech litigation lawyers shares her insights. Sara Thompson doesn’t take any guff when she tells people that she defends medical device and pharmaceutical companies from lawsuits. “I say,… […]